Dandi BioSciences

Dandi BioSciences is a South Korean biotechnology company dedicated to developing innovative peptide-based therapeutics and vaccine adjuvants. The company's core research focuses on neutralizing endotoxins, specifically lipopolysaccharides, to treat severe inflammatory conditions and infectious diseases. Its lead candidate, DD-S052, is being evaluated for the treatment of sepsis and liver cirrhosis by inhibiting the Toll-like receptor 4 (TLR4) pathway to prevent cytokine storms. Additionally, Dandi BioSciences is advancing a pipeline of 'smart' vaccine adjuvants designed to enhance the efficacy of both prophylactic and therapeutic vaccines. The company leverages its proprietary platform to create targeted solutions for high-unmet-need areas, including multidrug-resistant bacterial infections.